Condition (MeSH)
Carcinoma, Pancreatic Ductal
ClinicalTrials.gov lists 57 trials for Carcinoma, Pancreatic Ductal or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
57 of the 57 trials are tagged with Carcinoma, Pancreatic Ductal itself; the rest are tagged with a narrower condition beneath it.
When did Carcinoma, Pancreatic Ductal trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2024 | 5 |
| 2023 | 1 |
| 2022 | 7 |
| 2021 | 2 |
| 2020 | 4 |
| 2019 | 3 |
| 2018 | 2 |
| 2017 | 1 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 12 trials still running at the 2026-10-09 snapshot; registered median of 34 months across 32 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Carcinoma, Pancreatic Ductal trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 11 |
| Phase 1/2 | 9 |
| Phase 2 | 13 |
| Phase 3 | 4 |
| Not applicable | 8 |
| Observational | 12 |
How many Carcinoma, Pancreatic Ductal trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 7 |
| Active, not recruiting | 6 |
| Completed | 24 |
| Terminated | 6 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Carcinoma, Pancreatic Ductal trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pfizer | 4 |
| Revolution Medicines, Inc. | 4 |
| Allist Pharmaceuticals, Inc. | 2 |
| Angiodynamics, Inc. | 2 |
| Halozyme Therapeutics | 2 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Carcinoma, Pancreatic Ductal? (8)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| NAB paclitaxel | 9 |
| OXALIPLATIN | 4 |
| Daraxonrasib | 3 |
| Sasanlimab | 3 |
| CETUXIMAB | 3 |
Showing 5 of 8 drugs.
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Gemcitabine/Gemzar | 12 |
| or carboplatin | 3 |
| Fluorouracile | 3 |
| Bevacizumab 1 | 3 |
| Cisplatin 1 | 2 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Carcinoma, Pancreatic Ductal trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pyrexia | 125 | 4 |
| Abdominal pain | 99 | 4 |
| Sepsis | 97 | 4 |
| Disease progression | 91 | 2 |
| Vomiting | 83 | 4 |
Showing 5 of 10 adverse events.
Which publications cover Carcinoma, Pancreatic Ductal? (591)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future. | CA: a cancer journal for clinicians | 2026 | Yes |
| Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial. | Lancet (London, England) | 2026 | Yes |
| Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial. | Nature medicine | 2026 | Yes |
| Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications. | Seminars in cancer biology | 2025 | Yes |
| A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma. | Signal transduction and targeted therapy | 2025 | Yes |
Showing 5 of 591 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.